निलोटिनिब और पाज़ोपैनिब का इंटरैक्शन

Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP.

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval.

Transporters Coadministration of strong inhibitors of P-gp or BCRP may increase pazopanib concentrations.

Consider selection of alternative concomitant medicinal products with no or minimal potential to inhibit P-gp or BCRP.

Drugs That Prolong the QT Interval VOTRIENT is associated with QTc interval prolongation [see Warnings and Precautions (5.2), Clinical Pharmacology (12.2)] .